Polymyositis (PM) and Dermatomyositis (DM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Polymyositis (PM) and Dermatomyositis (DM) Market Outlook

Thelansis’s “Polymyositis (PM) and Dermatomyositis (DM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polymyositis (PM) and Dermatomyositis (DM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Polymyositis (PM) and Dermatomyositis (DM) Overview

Polymyositis (PM) and Dermatomyositis (DM) are autoimmune muscle diseases that lead to muscle inflammation, weakness in the proximal muscles, and additional symptoms. Both muscle weakness and a skin rash characterize DM. While these conditions share common clinical and histological features, such as muscle weakness and muscle inflammation seen in biopsies, they also have distinct differences in their presentation and underlying mechanisms. Patients with PM and DM usually experience a gradual onset of symmetrical proximal muscle weakness, often accompanied by elevated serum creatine kinase levels. Electromyography and magnetic resonance imaging (MRI) reveal similarities in both diseases. In DM, skin biopsies from affected areas display limited inflammatory cell infiltration at the dermo-epidermal junction, resembling the histopathological features of cutaneous lupus. These dermal infiltrates include activated T cells and immune complex deposition along vessel walls in the dermis. In contrast, PM is characterized by CD8+ T cells and macrophages within the myofibers. Moreover, PM is associated with an upregulation of MHC-I. This protein facilitates the entry of cytotoxic proteases and calcium into target cells, a characteristic feature of the condition.

• In the USA, Polymyositis and Dermatomyositis (PM/DM) range from 8 to 12 cases per 100,000 population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: